about
Antidepressants for smoking cessationDevelopment and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases.Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model processPerformance of a semi-automated approach for risk estimation using a common data model for longitudinal healthcare databases.Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) project.The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UKGovernance of conflicts of interest in postmarketing surveillance research and the Canadian Drug Safety and Effectiveness NetworkQuality of methods for assessing and reporting serious adverse events in clinical trials of cancer drugs.Today's challenges in pharmacovigilance: what can we learn from epoetins?Similarities between the discovery and regulation of pharmaceuticals and pesticides: in support of a better understanding of the risks and benefits of each.Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay--a systematic review.Should benefit-risk assessment have its own drug "label"?U.S. pharmacy policy: a public health perspective on safety and cost.Food and Drug Administration.Observational evidence for determining drug safety.Do statins prevent or promote cancer?Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.Clinical perspectives in drug safety and adverse drug reactions.A Semantic Transformation Methodology for the Secondary Use of Observational Healthcare Data in Postmarketing Safety Studies.Insurance coverage for pharmacogenomic testing in the USA
P2860
Q24246426-E1CD5F6C-D0E3-4E60-A2FC-F05657736251Q33723762-24E2D094-CD6E-4D68-8E5C-80BE4BB6D644Q33907196-65649E0B-AF95-4947-8BC7-9065C26B75D1Q33934896-ED3DFA61-F5F8-40C5-B86A-F6CE324DE5D7Q34370603-D3609356-15C0-4BA5-90E2-80B76D773205Q34828998-E1F338D3-45BE-44D7-B58A-B5865C6CC38EQ35049886-12FD865B-AB53-4105-A536-B11AC8B1398BQ37767130-110177FA-6338-4A2C-AA15-D6E179E9C817Q37854580-3B519D36-78A7-4AE4-A3EB-DBD4B8FD40D9Q37869061-5F9804DC-2E23-4AF9-9236-F60497B7463BQ38129733-CBABFFB1-7748-488C-A099-7A6BF846002BQ38271655-8AF35D3B-6DE4-42C2-995A-D4E4F4695D8FQ39939660-788ABE75-DD23-48B3-882E-80FB553BE3F4Q43016086-A01A8517-DC0F-48D9-8AC8-8365425AC3D6Q43081594-03BBEAD4-14CD-4169-B0CB-5E7FD007B955Q43204002-1CA79F5B-E66A-44D4-9ED0-40472C3E8BA2Q46657336-0FAB74E8-6BA6-407E-BE27-E5347659A74BQ46975372-A41A4910-D81A-44A7-84C2-CAD49838F2B2Q55109610-D04E5E02-B00F-48AF-9173-944CDA6C6395Q57404311-23E289FD-7A8E-4A5F-8650-74AF3C487127
P2860
description
im Oktober 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2006
@uk
name
The FDA and Drug Safety
@en
The FDA and Drug Safety
@nl
type
label
The FDA and Drug Safety
@en
The FDA and Drug Safety
@nl
prefLabel
The FDA and Drug Safety
@en
The FDA and Drug Safety
@nl
P1476
The FDA and Drug Safety
@en
P2093
Curt D. Furberg
P356
10.1001/ARCHINTE.166.18.1938
P407
P577
2006-10-09T00:00:00Z